X0508 4 2025-03-01 0001781174 Acrivon Therapeutics, Inc. ACRV 0001950499 Blume-Jensen Peter C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true President and CEO 0001950501 Masson Kristina C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 true true EVP - Business Operations false Stock Option (Right to Buy) 5.31 2025-03-01 4 A 0 390390 0 A 2035-02-28 Common Stock 390390 390390 D Stock Option (Right to Buy) 5.31 2025-03-01 4 A 0 140540 0 A 2035-02-28 Common Stock 140540 140540 I See Footnote Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen 2025-03-04 /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Kristina Masson 2025-03-04